Ser616

Site Information
PIPIMPAsPQKGHAV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454690
Available spectra: 1 CST
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoassay ( 1 , 4 , 8 , 11 , 21 , 26 , 30 , 35 , 40 , 49 , 53 , 56 ) , immunoprecipitation ( 33 , 61 ) , labeling using "Shokat-modified" upstream kinase ( 160 ) , mass spectrometry ( 51 , 65 , 66 , 69 , 71 , 74 , 75 , 77 , 78 , 79 , 80 , 81 , 83 , 84 , 85 , 86 , 88 , 89 , 90 , 91 , 92 , 93 , 95 , 96 , 97 , 98 , 100 , 101 , 103 , 104 , 105 , 106 , 107 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 ) , mass spectrometry (in vitro) ( 160 , 169 ) , microscopy-colocalization with upstream kinase ( 82 ) , modification-specific antibody ( 33 ) , mutation of modification site ( 1 , 5 , 8 , 21 , 28 , 33 , 44 , 53 , 56 , 61 , 72 , 73 , 82 , 102 , 159 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 62 , 63 , 64 , 68 , 70 , 72 , 73 , 76 , 82 , 99 , 102 , 159 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 63 , 64 , 68 , 70 , 72 , 73 , 76 , 82 , 99 , 102 , 159 )
Disease tissue studied:	bone cancer ( 11 ) , brain cancer ( 15 , 49 ) , glioblastoma ( 15 , 49 ) , glioma ( 15 , 49 ) , breast cancer ( 17 , 23 , 42 , 77 , 78 , 90 , 91 ) , breast ductal carcinoma ( 77 ) , HER2 positive breast cancer ( 66 ) , luminal A breast cancer ( 66 ) , luminal B breast cancer ( 66 ) , breast cancer, surrounding tissue ( 66 ) , breast cancer, triple negative ( 66 , 77 ) , cervical cancer ( 136 ) , cervical adenocarcinoma ( 136 ) , colorectal cancer ( 14 , 28 ) , colorectal carcinoma ( 14 , 28 ) , hypopharyngeal cancer ( 53 ) , kidney cancer ( 10 , 20 ) , leukemia ( 7 , 92 , 95 , 137 , 138 , 139 , 141 , 142 , 176 , 177 , 178 , 200 , 201 , 202 , 206 , 207 , 213 ) , acute lymphocytic leukemia ( 111 ) , acute myelogenous leukemia ( 7 , 92 , 95 , 141 , 142 , 176 , 177 , 178 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 89 ) , acute megakaryoblastic leukemia (M7) ( 89 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 89 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 89 ) , acute myeloblastic leukemia, without maturation (M1) ( 89 ) , chronic lymphocytic leukemia ( 206 , 207 , 213 ) , chronic myelogenous leukemia ( 137 , 138 , 139 , 200 , 201 , 202 ) , liver cancer ( 1 , 16 , 21 , 27 , 57 ) , hepatocellular carcinoma ( 21 , 27 ) , lung cancer ( 1 , 55 , 83 , 84 , 85 , 91 , 104 , 107 , 112 , 203 , 205 , 208 ) , non-small cell lung cancer ( 1 , 55 , 84 , 91 ) , non-small cell lung adenocarcinoma ( 1 , 55 , 84 , 85 , 104 ) , non-small cell large cell lung carcinoma ( 55 ) , small-cell lung cancer ( 83 , 203 , 205 , 208 ) , lymphoma ( 79 ) , B cell lymphoma ( 89 ) , Burkitt's lymphoma ( 79 ) , non-Hodgkin's lymphoma ( 89 ) , follicular lymphoma ( 79 ) , mantle cell lymphoma ( 79 ) , nasopharyngeal carcinoma ( 53 ) , neuroblastoma ( 1 , 8 , 30 , 34 , 44 , 61 ) , ovarian cancer ( 18 , 25 , 77 ) , multiple myeloma ( 2 , 89 ) , prostate cancer ( 5 , 49 ) , melanoma skin cancer ( 68 , 71 , 72 ) , LUAD ( 26 ) , Parkinson's disease ( 59 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 12 , 58 ) , 'muscle, smooth' ( 3 ) , 'muscle, smooth'-pulmonary artery ( 9 ) , 'neuron, cortical' ( 13 ) , 'stem, mesenchymal' ( 63 ) , 22Rv1 (prostate cell) ( 5 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 129 ) , 293 (epithelial) ( 22 , 37 , 75 , 119 , 120 , 151 ) , 293E (epithelial) ( 103 ) , 786-O (renal) [VHL (human), transfection] ( 69 ) , 786-O (renal) ( 69 ) , 95-C ( 24 ) , 95-D ( 24 ) , A2780 (ovarian) ( 18 ) , A375 (melanocyte) ( 68 , 72 ) , A498 (renal) ( 130 ) , A549 (pulmonary) ( 1 , 55 , 107 ) , AC16 ( 47 ) , adipocyte-adipose tissue ( 28 ) , AML-193 (monocyte) ( 89 ) , ARPE19 (retinal) ( 48 ) , B lymphoid-blood ( 213 ) , BJ (fibroblast) ( 33 ) , BJAB (B lymphocyte) ( 79 ) , bone marrow ( 111 , 141 , 142 , 176 , 177 , 178 ) , brain ( 59 , 76 ) , breast ( 66 , 77 ) , BT-20 (breast cell) ( 91 ) , BT-549 (breast cell) ( 91 ) , BxPC-3 (pancreatic) ( 209 , 210 ) , Caki-1 (renal) ( 10 , 20 ) , Calu 6 (pulmonary) ( 91 ) , CL1-0 (pulmonary) ( 112 ) , CL1-1 (pulmonary) ( 112 ) , CL1-2 (pulmonary) ( 112 ) , CL1-5 (pulmonary) ( 112 ) , CMK (megakaryoblast) ( 89 ) , CNE1-LMP1 ( 53 ) , CNE1 ( 53 ) , COC1/DDP ( 18 ) , COS (fibroblast) ( 173 ) , CTS (myeloid) ( 89 ) , DMS153 (pulmonary) ( 84 , 203 ) , DMS53 (pulmonary) ( 83 , 199 ) , DMS79 (pulmonary) ( 198 ) , DOHH2 ('B lymphocyte, precursor') ( 89 ) , EA.hy 926 (endothelial) ( 35 , 46 ) , endothelial-aorta ( 31 ) , fibroblast-foreskin ( 42 ) , FL-18 (B lymphocyte) ( 79 ) , FL-318 (B lymphocyte) ( 79 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 93 ) , Flp-In T-Rex-293 (epithelial) ( 93 ) , glial-brain ( 32 ) , H2009 (pulmonary) ( 91 ) , H2077 (pulmonary) ( 91 ) , H2887 (pulmonary) ( 91 ) , H322M (pulmonary) ( 91 ) , H9c2 (myoblast) ( 47 , 52 ) , HCC1359 (pulmonary) ( 91 ) , HCC1937 (breast cell) ( 91 ) , HCC2279 (pulmonary) ( 91 ) , HCC366 (pulmonary) ( 91 ) , HCC4006 (pulmonary) ( 91 ) , HCC78 (pulmonary) ( 91 ) , HCT116 (intestinal) ( 28 ) , HCT15 (intestinal) ( 14 ) , heart ( 64 ) , HEK293T (epithelial) ( 33 , 61 ) , HEL (erythroid) ( 89 , 190 , 191 ) , HeLa (cervical) ( 6 , 41 , 65 , 70 , 74 , 82 , 88 , 96 , 99 , 110 , 114 , 116 , 117 , 118 , 140 , 156 , 157 , 159 , 161 , 162 , 163 , 164 , 165 , 171 , 172 , 211 , 212 ) , HeLa S3 (cervical) ( 136 ) , HepG2 (hepatic) ( 1 , 16 , 21 ) , HFF1 (fibroblast) ( 22 ) , HK2 (epithelial) ( 19 , 60 ) , HLMVECs ( 36 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 78 ) , HMLER ('stem, breast cancer') ( 78 ) , HNE-2 ( 53 ) , HONE-1 ( 53 ) , HOP62 (pulmonary) ( 91 ) , HUES-7 ('stem, embryonic') ( 143 ) , HUES-9 ('stem, embryonic') ( 109 ) , Huh7 (hepatic) ( 27 ) , IMR32 (neural crest) ( 34 ) , JEKO-1 (B lymphocyte) ( 79 ) , Jurkat (T lymphocyte) ( 86 , 97 , 98 , 100 , 101 , 105 , 106 , 113 , 115 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 131 , 132 , 133 , 134 , 135 , 154 , 155 , 158 , 166 , 167 , 168 , 174 ) , K562 (erythroid) ( 88 , 137 , 138 , 139 , 140 , 144 , 145 , 200 , 201 , 202 ) , Kasumi-1 (myeloid) ( 89 ) , KG-1 (myeloid) ( 89 , 95 ) , kidney ( 20 , 56 ) , KMS-11 (B lymphocyte) ( 2 ) , Kyse140 (esophageal) ( 181 , 182 ) , Kyse270 (esophageal) ( 189 ) , LAD2 (mast) ( 39 ) , LAPC-4 (prostate cell) ( 5 ) , liver ( 21 , 81 ) , LN229 (glial) ( 49 ) , LOU-NH91 (squamous) ( 91 ) , lung ( 55 , 83 , 84 , 85 ) , macrophage-bone marrow ( 40 ) , MCF-7 (breast cell) ( 17 , 23 , 42 , 91 ) , MDA-MB-231 (breast cell) ( 91 ) , MDA-MB-468 (breast cell) ( 91 ) , MEC1 (B lymphocyte) ( 206 ) , MEC2 (B lymphocyte) ( 207 ) , MEF (fibroblast) ( 28 , 40 , 55 , 62 , 72 , 102 ) , MHCC97H (hepatic) ( 21 ) , Molm 14 (myeloid) ( 146 , 148 , 179 , 180 ) , MV4-11 (macrophage) ( 89 , 92 , 150 , 183 , 184 ) , myoblast ( 58 ) , myocyte-heart ( 43 ) , N1E-115 (neuron) ( 44 ) , NCEB-1 (B lymphocyte) ( 79 ) , NCI-H128 (pulmonary) ( 192 , 193 ) , NCI-H1299 (pulmonary) ( 55 ) , NCI-H1395 (pulmonary) ( 91 ) , NCI-H1437 (pulmonary) ( 84 ) , NCI-H1568 (pulmonary) ( 91 ) , NCI-H157 (pulmonary) ( 91 ) , NCI-H1648 (pulmonary) ( 91 ) , NCI-H1666 (pulmonary) ( 91 ) , NCI-H1703 (squamous) ( 152 , 204 ) , NCI-H2030 (pulmonary) ( 91 ) , NCI-H2073 (pulmonary) ( 84 ) , NCI-H209 (pulmonary) ( 84 ) , NCI-H2172 (pulmonary) ( 91 ) , NCI-H322 (pulmonary) ( 91 ) , NCI-H446 (pulmonary) ( 83 , 194 , 195 ) , NCI-H460 (pulmonary) ( 55 , 91 ) , NCI-H520 (squamous) ( 91 ) , NCI-H526 (pulmonary) ( 83 , 208 ) , NCI-H647 (pulmonary) ( 91 ) , NCI-H69 (pulmonary) ( 83 , 205 ) , NCI-H82 (pulmonary) ( 83 ) , NCI-H838 (pulmonary) ( 84 ) , Neuro-2a (neuron) ( 44 ) , neuron-'brain, cerebral cortex' ( 82 ) , neuron-'brain, hippocampus' ( 30 , 82 ) , NRK49F (fibroblast) ( 56 ) , OCI-ly1 (B lymphocyte) ( 79 ) , oocyte ( 45 ) , OPM-2 (plasma cell) ( 89 ) , ovary ( 77 ) , P31/FUJ (erythroid) ( 89 , 92 ) , PA-1 (ovarian) ( 25 ) , PC3 (prostate cell) ( 49 ) , PC9 (pulmonary) ( 91 ) , platelet-blood ( 170 ) , prostate ( 5 ) , PT130 ( 28 ) , R28 (retinal) ( 38 ) , Raji (B lymphocyte) ( 79 ) , RAMOS (B lymphocyte) ( 79 ) , REC-1 (B lymphocyte) ( 79 ) , RL ('B lymphocyte, precursor') ( 89 ) , RPE-1 (retinal) ( 29 ) , RPMI-8266 (plasma cell) ( 89 ) , SEM (B lymphocyte) ( 147 , 149 , 185 , 186 , 187 , 188 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 80 ) , SH-SY5Y (neural crest) ( 1 , 8 , 61 , 80 ) , SKBr3 (breast cell) ( 90 ) , SKNSH (neural crest) ( 30 , 34 ) , SMMC7721 (hepatocyte) ( 57 ) , SNU-449 (hepatic) ( 27 ) , spinal cord ( 4 ) , stem ( 32 ) , SU-DHL-4 (B lymphocyte) ( 79 ) , SU-DHL-6 (B lymphocyte) ( 89 ) , SW480 (intestinal) ( 28 ) , T-ALL (T lymphocyte) ( 63 ) , THP1 (myeloid) ( 7 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 104 ) , U-1810 (pulmonary) ( 104 ) , U-251 MG (glial) ( 15 ) , U266 (plasma cell) ( 89 ) , U2OS (bone cell) ( 11 ) , U87MG (glial) ( 15 ) , UPN-1 (B lymphocyte) ( 79 ) , Vero E6-S ('epithelial, kidney') ( 51 ) , WM115 (melanocyte) ( 153 ) , WM239A (melanocyte) ( 71 ) , ZR-75-1 (breast cell) ( 17 , 23 )

Upstream Regulation
Regulatory protein:	ASNS (human) ( 24 ) , BLOC1S1 (human) ( 16 ) , BORIS (human) ( 34 ) , CDK5R1 (human) ( 59 ) , CNR1 (human) ( 60 ) , CPT1A (human) ( 32 ) , CUL4A (human) ( 18 ) , DAP3 (human) ( 70 ) , DDAH2 (human) ( 40 ) , DDB1 (human) ( 18 ) , DRP1 (human) ( 1 ) , ERK1 (human) ( 59 ) , FUNDC1 (human) ( 49 ) , HIF1A (human) ( 25 ) , HMGB1 (human) ( 46 ) , LCN2 (human) ( 6 , 59 ) , LIMK2 (human) ( 76 ) , LMP1 (herpesvirus) ( 53 ) , MEK1 (human) ( 33 , 43 ) , MLXIP (human) ( 29 ) , MYH9 (human) ( 27 ) , MYO1F (human) ( 39 ) , NuaK1 (human) ( 2 ) , OTUB1 (human) ( 20 ) , PARK2 (human) ( 21 ) , PGAM5 (human) ( 22 ) , PIEZO1 (human) ( 4 ) , Pim1 (human) ( 55 ) , PKCD (human) ( 38 ) , PPP2R5C (human) ( 21 ) , PRDX3 (human) ( 29 ) , PRSS15 (human) ( 49 ) , PXN (human) ( 36 ) , RAB32 (human) ( 15 ) , RALA (human) ( 99 ) , RALBP1 (human) ( 99 ) , Raptor (human) ( 10 , 20 ) , SHP-2 (human) ( 10 ) , SIRT6 (human) ( 25 ) , Src (human) ( 20 ) , STMP1 (human) ( 27 ) , streptavidin (bacteria) ( 39 )
Putative in vivo kinases:	Akt1 (human) ( 48 ) , CDK1 (human) ( 53 ) , CDK5 (human) ( 44 , 59 , 82 ) , ERK1 (human) ( 17 , 25 , 27 , 28 , 36 , 48 , 60 ) , ERK2 (human) ( 17 , 25 , 27 , 36 , 60 , 73 ) , GSK3B (human) ( 30 ) , PKCD (human) ( 108 )
Kinases, in vitro:	CDK1 (human) ( 99 , 169 ) , CDK2 (human) ( 160 ) , ERK1 (human) ( 72 ) , ERK2 (human) ( 72 , 73 )
Putative upstream phosphatases:	PPP2R5C (human) ( 21 )
Treatments:	ARCC-4 ( 5 ) , (S)-lacosamide ( 13 ) , 3-(2-Aminoethyl)-5-((4-ethoxyphenyl)methylene)-2,4-thiazolidinedione, HCl ( 25 ) , A769662 ( 48 ) , adriamycin ( 29 , 47 , 52 ) , anandamide ( 60 ) , antimycin_A ( 41 ) , apalutamide ( 5 ) , AZD1208 ( 55 ) , bacterial infection ( 35 ) , butaprost ( 9 ) , carnitine ( 16 ) , CCCP ( 21 , 41 ) , cisplatin ( 53 ) , CoCl2 ( 14 ) , coculture ( 63 ) , copper ( 57 ) , CsA ( 11 ) , Cucurbitacin-E ( 53 ) , dasatinib ( 140 ) , deltaV1-1 ( 108 ) , development ( 45 ) , docetaxel ( 55 ) , doxycycline ( 76 ) , Dynasore ( 41 ) , enzalutamide ( 5 ) , etomoxir ( 16 ) , exercise training ( 12 ) , flavopiridol ( 76 ) , fluorouracil ( 21 ) , fungal infection ( 22 ) , G-1 ( 17 ) , H-89 ( 9 ) , H2O2 ( 108 ) , hexafluoro ( 68 ) , honokiol DCA ( 68 ) , hypothermia ( 31 ) , hypoxia ( 37 , 43 ) , hypoxia/reoxygenation ( 19 ) , IgE ( 39 ) , ionomycin ( 11 ) , ischemia ( 43 , 77 ) , KB SRC 4 ( 20 ) , KN-93 ( 11 , 38 ) , L-glutamine_withdrawal ( 23 ) , LCB 03-0100 ( 20 ) , LIGHT ( 11 , 19 , 38 ) , lncRNAs ( 7 ) , LPS ( 36 ) , LRRK2-IN-1 ( 80 ) , luteolin ( 47 ) , Mdivi-1 ( 32 , 35 , 37 , 40 , 41 , 45 ) , melatonin ( 45 ) , metformin ( 48 ) , MPTP ( 59 ) , MRE-269 ( 9 ) , NAC ( 16 , 57 ) , NaIO3 ( 48 ) , nicotinamide ( 42 ) , nocodazole ( 41 , 136 ) , obesity ( 58 ) , odanacatib ( 10 ) , OGD/R ( 8 , 44 ) , oleic_acid ( 28 ) , palmitate ( 16 , 28 ) , PD0325901 ( 37 , 63 , 73 ) , PD98059 ( 4 , 17 , 36 , 38 , 43 ) , PDGF ( 62 ) , PF04418948 ( 9 ) , PIM447 ( 55 ) , pirinixic acid ( 76 ) , R03306 ( 108 ) , RO-3306 ( 11 ) , RO1138452 ( 9 ) , rotenone ( 41 ) , SB525334 ( 27 ) , SCH772984 ( 4 , 15 ) , seliciclib ( 38 , 44 , 63 ) , serum ( 73 ) , sevoflurane ( 30 ) , Shenmai ( 52 ) , siRNA ( 21 , 28 , 44 , 53 ) , starvation ( 102 ) , status epilepticus ( 76 ) , stiff ECM substrate ( 4 ) , substance_P ( 39 ) , tamoxifen ( 23 ) , TDZD-8 ( 30 ) , TGF-beta ( 56 ) , TNF ( 3 ) , Trametinib ( 28 ) , Treprostinil ( 9 ) , Trolox ( 38 ) , U0126 ( 11 , 16 , 27 , 48 , 153 ) , unilateral ureteral obstruction ( 56 ) , virus infection ( 40 ) , Wnt3a ( 24 ) , Y27632 ( 76 )

Downstream Regulation
Effects of modification on DRP1:	acetylation ( 56 ) , activity, induced ( 26 , 32 , 34 , 55 , 57 , 59 , 102 ) , enzymatic activity, inhibited ( 30 ) , intracellular localization ( 11 , 21 , 28 , 31 , 35 , 38 , 39 , 40 , 53 , 55 , 62 , 108 ) , molecular association, regulation ( 21 , 28 ) , phosphorylation ( 30 , 40 ) , protein conformation ( 82 )
Effects of modification on biological processes:	apoptosis, induced ( 17 , 30 , 43 , 44 , 55 , 57 , 108 ) , apoptosis, inhibited ( 21 , 30 , 53 , 56 ) , autophagy, induced ( 8 , 12 , 21 , 28 ) , carcinogenesis, induced ( 15 , 16 , 21 , 25 , 27 , 28 , 32 , 49 , 53 ) , carcinogenesis, inhibited ( 24 , 55 ) , cell differentiation, inhibited ( 32 ) , cell growth, induced ( 9 , 56 , 73 ) , cell growth, inhibited ( 24 , 48 , 57 ) , cell motility, induced ( 15 , 16 , 25 , 27 , 49 ) , cytoskeletal reorganization ( 25 , 48 , 62 , 82 ) , exocytosis, induced ( 39 ) , signaling pathway regulation ( 28 , 40 , 57 , 59 ) , transcription, altered ( 56 ) , transcription, induced ( 28 , 40 )
Induce interaction with:	DRP1 (human) ( 28 ) , MFF (human) ( 28 ) , Rab7 (human) ( 21 )

Disease / Diagnostics Relevance
Relevant diseases:	Alzheimer's disease ( 13 ) , kidney cancer ( 20 ) , nasopharyngeal carcinoma ( 53 ) , pancreatic carcinoma ( 73 ) , cardiomyopathy ( 64 ) , Parkinson's disease ( 59 ) , PAH ( 9 )

References
1	Das P, Chakrabarti O (2024) ISGylation of DRP1 closely balances other post-translational modifications to mediate mitochondrial fission. Cell Death Dis 15, 184 38431611 Curated Info
2	Karnan S, et al. (2024) ARK5 enhances cell survival associated with mitochondrial morphological dynamics from fusion to fission in human multiple myeloma cells. Cell Death Discov 10, 56 38282096 Curated Info
3	Dasgupta D, et al. (2023) Molecular Mechanisms Underlying TNFα Induced Mitochondrial Fragmentation in Human Airway Smooth Muscle Cells. Am J Physiol Lung Cell Mol Physiol 38084427 Curated Info
4	Ke W, et al. (2023) Matrix stiffness induces Drp1-mediated mitochondrial fission through Piezo1 mechanotransduction in human intervertebral disc degeneration. J Transl Med 21, 711 37817199 Curated Info
5	Crowell PD, et al. (2023) MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell Rep 42, 113221 37815914 Curated Info
6	Marques E, et al. (2023) Lipocalin-2 induces mitochondrial dysfunction in renal tubular cells via mTOR pathway activation. Cell Rep 42, 113032 37624695 Curated Info
7	Karger A, et al. (2023) ADPGK-AS1 long noncoding RNA switches macrophage metabolic and phenotypic state to promote lung cancer growth. EMBO J 42, e111620 37545364 Curated Info
8	Yuan ZL, et al. (2023) Inhibition of ERK downregulates autophagy via mitigating mitochondrial fragmentation to protect SH-SY5Y cells from OGD/R injury. Cell Commun Signal 21, 204 37580749 Curated Info
9	Abu-Hanna J, et al. (2023) Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertension. Vascul Pharmacol 151, 107194 37442283 Curated Info
10	Seo SU, Woo SM, Kwon TK (2023) Cathepsin K inhibition induces Raptor destabilization and mitochondrial dysfunction via Syk/SHP2/Src/OTUB1 axis-mediated signaling. Cell Death Dis 14, 366 37330581 Curated Info
11	Lai YS, et al. (2023) Optogenetically engineered Ca2+ oscillation-mediated DRP1 activation promotes mitochondrial fission and cell death. J Cell Sci 136 37232206 Curated Info
12	Yamauchi N, et al. (2023) High-intensity interval training in the form of isometric contraction improves fatigue resistance in dystrophin-deficient muscle. J Physiol 37184335 Curated Info
13	Brustovetsky T, Khanna R, Brustovetsky N (2023) CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer's Disease. Cells 12 37174687 Curated Info
14	Ponneri Babuharisankar A, et al. (2023) Mitochondrial Lon-induced mitophagy benefits hypoxic resistance via Ca-dependent FUNDC1 phosphorylation at the ER-mitochondria interface. Cell Death Dis 14, 199 36927870 Curated Info
15	Chen P, et al. (2023) Rab32 promotes glioblastoma migration and invasion via regulation of ERK/Drp1-mediated mitochondrial fission. Cell Death Dis 14, 198 36922509 Curated Info
16	Han L, et al. (2023) Retrograde regulation of mitochondrial fission and epithelial to mesenchymal transition in hepatocellular carcinoma by GCN5L1. Oncogene 36759571 Curated Info
17	Rekha P, et al. (2023) GPER induces mitochondrial fission through p44/42 MAPK - Drp1 pathway in breast cancer cells. Biochem Biophys Res Commun 643, 16-23 36584588 Curated Info
18	Meng Y, et al. (2022) Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy. Signal Transduct Target Ther 7, 388 36481655 Curated Info
19	Zheng QY, et al. (2022) LIGHT deficiency attenuates acute kidney disease development in an in vivo experimental renal ischemia and reperfusion injury model. Cell Death Discov 8, 399 36163116 Curated Info
20	Seo SU, et al. (2022) Phosphorylation of OTUB1 at Tyr 26 stabilizes the mTORC1 component, Raptor. Cell Death Differ 30 35927303 Curated Info
21	Che L, et al. (2022) Protein phosphatase 2A-B56γ-Drp1-Rab7 signaling axis regulates mitochondria-lysosome crosstalk to sensitize the anti-cancer therapy of hepatocellular carcinoma. Biochem Pharmacol 202, 115132 35697120 Curated Info
22	Luo J, et al. (2022) Microsporidia Promote Host Mitochondrial Fragmentation by Modulating DRP1 Phosphorylation. Int J Mol Sci 23 35887094 Curated Info
23	Vijayakumar G, Swetha US, Sudhagar S (2022) Tamoxifen modulates mitochondrial dynamics through AMPK and MAPK during nutrition deprivation. Cell Biol Int 35819094 Curated Info
24	Cai DJ, et al. (2022) Asparagine synthetase regulates lung-cancer metastasis by stabilizing the β-catenin complex and modulating mitochondrial response. Cell Death Dis 13, 566 35739087 Curated Info
25	Bandopadhyay S, et al. (2022) SIRT6 promotes mitochondrial fission and subsequent cellular invasion in ovarian cancer. FEBS Open Bio 35686673 Curated Info
26	Huang YL, et al. (2022) Prognostic significance of dynamin-related protein 1 expression in advanced lung adenocarcinoma. Pathol Res Pract 234, 153931 35523103 Curated Info
27	Xie C, et al. (2022) Mitochondrial micropeptide STMP1 enhances mitochondrial fission to promote tumor metastasis. Cancer Res 82 35544764 Curated Info
28	Xiong X, et al. (2022) Activation of Drp1 promotes fatty acids-induced metabolic reprograming to potentiate Wnt signaling in colon cancer. Cell Death Differ 35332310 Curated Info
29	Yamamoto-Imoto H, et al. (2022) Age-associated decline of MondoA drives cellular senescence through impaired autophagy and mitochondrial homeostasis. Cell Rep 38, 110444 35235784 Curated Info
30	Liu J, et al. (2022) Sevoflurane induced neurotoxicity in neonatal mice links to a GSK3β/Drp1-dependent mitochondrial fission and apoptosis. Free Radic Biol Med 181, 72-81 35122996 Curated Info
31	Quiring L, et al. (2022) Characterisation of cold-induced mitochondrial fission in porcine aortic endothelial cells. Mol Med 28, 13 35100966 Curated Info
32	Luo M, et al. (2021) Overexpression of carnitine palmitoyltransferase 1A promotes mitochondrial fusion and differentiation of glioblastoma stem cells. Lab Invest 34963686 Curated Info
33	Cha Y, et al. (2021) SIRT2 regulates mitochondrial dynamics and reprogramming via MEK1-ERK-DRP1 and AKT1-DRP1 axes. Cell Rep 37, 110155 34965411 Curated Info
34	Makani VKK, et al. (2021) BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma. Free Radic Biol Med 176, 62-72 34534628 Curated Info
35	Xu T, et al. (2021) Porphyromonas gingivalis infection promotes mitochondrial dysfunction through Drp1-dependent mitochondrial fission in endothelial cells. Int J Oral Sci 13, 28 34475379 Curated Info
36	Fu P, et al. (2021) Essential role for paxillin tyrosine phosphorylation in LPS-induced mitochondrial fission, ROS generation and lung endothelial barrier loss. Sci Rep 11, 17546 34475475 Curated Info
37	Yuan Y, et al. (2021) Activation of ERK-Drp1 signaling promotes hypoxia-induced Aβ accumulation by upregulating mitochondrial fission and BACE1 activity. FEBS Open Bio 11 34403210 Curated Info
38	Yang D, et al. (2021) CaMK II -induced Drp1 phosphorylation contributes to blue light-induced AIF-mediated necroptosis in retinal R28 cells. Biochem Biophys Res Commun 559, 113-120 33940381 Curated Info
39	Navinés-Ferrer A, et al. (2021) MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis. J Immunol 206, 2277-2289 33941653 Curated Info
40	Huang S, et al. (2021) DDAH2 suppresses RLR-MAVS-mediated innate antiviral immunity by stimulating nitric oxide-activated, Drp1-induced mitochondrial fission. Sci Signal 14 33850055 Curated Info
41	Ko HJ, et al. (2021) The Phosphorylation Status of Drp1-Ser637 by PKA in Mitochondrial Fission Modulates Mitophagy via PINK1/Parkin to Exert Multipolar Spindles Assembly during Mitosis. Biomolecules 11 33805672 Curated Info
42	Song SB, Park JS, Jang SY, Hwang ES (2021) Nicotinamide Treatment Facilitates Mitochondrial Fission through Drp1 Activation Mediated by SIRT1-Induced Changes in Cellular Levels of cAMP and Ca. Cells 10 33802063 Curated Info
43	Zhao Q, et al. (2021) Constitutive activation of ERK1/2 signaling protects against myocardial ischemia via inhibition of mitochondrial fragmentation in the aging heart. Ann Transl Med 9, 479 33850876 Curated Info
44	Chen C, et al. (2021) CDK5 inhibition protects against OGDR induced mitochondrial fragmentation and apoptosis through regulation of Drp1S616 phosphorylation. Life Sci 269, 119062 33476635 Curated Info
45	Yang SG, et al. (2021) Melatonin Protects Against Mdivi-1-Induced Abnormal Spindle Assembly and Mitochondrial Superoxide Production During Porcine Oocyte Maturation. Front Cell Dev Biol 9, 693969 34307369 Curated Info
46	Zhang S, et al. (2021) Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells. Oxid Med Cell Longev 2021, 9993240 34394840 Curated Info
47	Shi Y, et al. (2021) Luteolin Prevents Cardiac Dysfunction and Improves the Chemotherapeutic Efficacy of Doxorubicin in Breast Cancer. Front Cardiovasc Med 8, 750186 34722681 Curated Info
48	Chan CM, et al. (2020) Different Effects of Metformin and A769662 on Sodium Iodate-Induced Cytotoxicity in Retinal Pigment Epithelial Cells: Distinct Actions on Mitochondrial Fission and Respiration. Antioxidants (Basel) 9 33126710 Curated Info
49	Li J, et al. (2020) The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells. Sci Signal 32723812 Curated Info
50	Kapetanovic R, et al. (2020) Lipopolysaccharide promotes Drp1-dependent mitochondrial fission and associated inflammatory responses in macrophages. Immunol Cell Biol 32686869 Curated Info
51	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
52	Li L, et al. (2020) Shenmai Injection Protects Against Doxorubicin-Induced Cardiotoxicity via Maintaining Mitochondrial Homeostasis. Front Pharmacol 32581790 Curated Info
53	Xie L, et al. (2020) Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduct Target Ther 5, 56 32433544 Curated Info
54	Simula L, et al. (2020) JNK1 and ERK1/2 modulate lymphocyte homeostasis via BIM and DRP1 upon AICD induction. Cell Death Differ 32346136 Curated Info
55	Chauhan SS, et al. (2020) PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer. Oncogene 31992853 Curated Info
56	Wang Y, et al. (2020) Drp1-mediated mitochondrial fission promotes renal fibroblast activation and fibrogenesis. Cell Death Dis 31949126 Curated Info
57	Shao J, et al. (2019) TPP-related mitochondrial targeting copper (II) complex induces p53-dependent apoptosis in hepatoma cells through ROS-mediated activation of Drp1. Cell Commun Signal 17, 149 31744518 Curated Info
58	Gundersen AE, et al. (2019) Altered Mitochondrial Network Morphology and Regulatory Proteins in Mitochondrial Quality Control in Myotubes from Severely Obese Humans With or Without Type 2 Diabetes. Appl Physiol Nutr Metab 31356754 Curated Info
59	Park J, et al. (2019) Abnormal Mitochondria in a Non-human Primate Model of MPTP-induced Parkinson's Disease: Drp1 and CDK5/p25 Signaling. Exp Neurobiol 28, 414-424 31308800 Curated Info
60	Drori A, et al. (2018) Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells. Diabetes Obes Metab 30091204 Curated Info
61	Zhou L, et al. (2017) c-Abl-mediated Drp1 phosphorylation promotes oxidative stress-induced mitochondrial fragmentation and neuronal cell death. Cell Death Dis 8, e3117 29022905 Curated Info
62	Jo Y, Cho HM, Sun W, Ryu JR (2017) Localization of dynamin-related protein 1 and its potential role in lamellipodia formation. Histochem Cell Biol 148, 13-20 28314909 Curated Info
63	Cai J, et al. (2016) ERK/Drp1-dependent mitochondrial fission is involved in the MSC-induced drug resistance of T-cell acute lymphoblastic leukemia cells. Cell Death Dis 7, e2459 27831567 Curated Info
64	Xu S, et al. (2016) CaMKII induces permeability transition through Drp1 phosphorylation during chronic β-AR stimulation. Nat Commun 7, 13189 27739424 Curated Info
65	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
66	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
67	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
68	Bonner MY, et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7, 12857-68 26871475 Curated Info
69	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
70	Xiao L, et al. (2015) Death-associated Protein 3 Regulates Mitochondrial-encoded Protein Synthesis and Mitochondrial Dynamics. J Biol Chem 290, 24961-74 26306039 Curated Info
71	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
72	Serasinghe MN, et al. (2015) Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell 57, 521-36 25658204 Curated Info
73	Kashatus JA, et al. (2015) Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell 57, 537-51 25658205 Curated Info
74	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
75	Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54 24965592 Curated Info
76	Kim JE, Ryu HJ, Kim MJ, Kang TC (2014) LIM kinase-2 induces programmed necrotic neuronal death via dysfunction of DRP1-mediated mitochondrial fission. Cell Death Differ 21, 1036-49 24561342 Curated Info
77	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
78	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
79	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
80	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
81	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
82	Cho B, et al. (2014) CDK5-dependent inhibitory phosphorylation of Drp1 during neuronal maturation. Exp Mol Med 46, e105 25012575 Curated Info
83	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
84	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
85	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
86	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
87	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
88	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
89	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
90	Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57 22964224 Curated Info
91	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
92	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
93	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
94	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
95	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
96	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
97	Guo A (2011) CST Curation Set: 12740; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
98	Guo A (2011) CST Curation Set: 12741; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
99	Kashatus DF, et al. (2011) RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol 13, 1108-15 21822277 Curated Info
100	Guo A (2011) CST Curation Set: 12437; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
101	Guo A (2011) CST Curation Set: 12039; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
102	Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J (2011) Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci U S A 108, 10190-5 21646527 Curated Info
103	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
104	Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78 21413766 Curated Info
105	Guo A (2011) CST Curation Set: 11424; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
106	Guo A (2011) CST Curation Set: 11425; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
107	Yu G, et al. (2011) Phosphoproteome profile of human lung cancer cell line A549. Mol Biosyst 7, 472-9 21060948 Curated Info
108	Qi X, et al. (2011) Aberrant mitochondrial fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in vivo. Mol Biol Cell 22, 256-65 21119009 Curated Info
109	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
110	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
111	Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169 21552520 Curated Info
112	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
113	Possemato A (2010) CST Curation Set: 10837; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
114	Zhou J (2010) CST Curation Set: 10708; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
115	Possemato A (2010) CST Curation Set: 10720; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
116	Zhou J (2010) CST Curation Set: 10709; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
117	Zhou J (2010) CST Curation Set: 10685; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
118	Zhou J (2010) CST Curation Set: 10684; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
119	Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
120	Guo A (2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
121	Possemato A (2010) CST Curation Set: 10053; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
122	Possemato A (2010) CST Curation Set: 10052; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
123	Possemato A (2010) CST Curation Set: 10055; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
124	Possemato A (2010) CST Curation Set: 10057; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
125	Possemato A (2010) CST Curation Set: 10054; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
126	Possemato A (2010) CST Curation Set: 10056; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
127	Possemato A (2010) CST Curation Set: 10050; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
128	Possemato A (2010) CST Curation Set: 10051; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
129	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
130	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
131	Possemato A (2010) CST Curation Set: 9791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
132	Possemato A (2010) CST Curation Set: 9396; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
133	Possemato A (2010) CST Curation Set: 9048; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
134	Possemato A (2010) CST Curation Set: 9044; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
135	Possemato A (2010) CST Curation Set: 9036; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
136	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
137	Moritz A (2009) CST Curation Set: 8719; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
138	Moritz A (2009) CST Curation Set: 8720; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
139	Moritz A (2009) CST Curation Set: 8722; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
140	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
141	Gu T (2009) CST Curation Set: 7660; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
142	Gu T (2009) CST Curation Set: 7659; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
143	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
144	Gu T (2009) CST Curation Set: 6993; Year: 2009; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
145	Gu T (2009) CST Curation Set: 6992; Year: 2009; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
146	Gu T (2009) CST Curation Set: 6980; Year: 2009; Biosample/Treatment: cell line, Molm 14/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
147	Gu T (2009) CST Curation Set: 6987; Year: 2009; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
148	Gu T (2009) CST Curation Set: 6981; Year: 2009; Biosample/Treatment: cell line, Molm 14/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
149	Gu T (2009) CST Curation Set: 6986; Year: 2009; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
150	Gu T (2009) CST Curation Set: 6974; Year: 2009; Biosample/Treatment: cell line, MV4-11/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
151	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
152	Zhou J (2009) CST Curation Set: 6867; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
153	Old WM, et al. (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34, 115-31 19362540 Curated Info
154	Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
155	Possemato A (2009) CST Curation Set: 6369; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
156	Zhou J (2009) CST Curation Set: 6250; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
157	Zhou J (2009) CST Curation Set: 6251; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
158	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
159	Cereghetti GM, et al. (2008) Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci U S A 105, 15803-8 18838687 Curated Info
160	Chi Y, et al. (2008) Identification of CDK2 substrates in human cell lysates. Genome Biol 9, R149 18847512 Curated Info
161	Moritz A (2008) CST Curation Set: 5058; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
162	Moritz A (2008) CST Curation Set: 5059; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
163	Moritz A (2008) CST Curation Set: 5080; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
164	Moritz A (2008) CST Curation Set: 5081; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
165	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
166	Guo A (2008) CST Curation Set: 4589; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
167	Possemato A (2008) CST Curation Set: 4342; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
168	Possemato A (2008) CST Curation Set: 4346; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381 Curated Info
169	Blethrow JD, Glavy JS, Morgan DO, Shokat KM (2008) Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc Natl Acad Sci U S A 105, 1442-7 18234856 Curated Info
170	Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34 18088087 Curated Info
171	Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6 18187866 Curated Info
172	Yu LR, et al. (2007) Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 6, 4150-62 17924679 Curated Info
173	Wang Y, et al. (2007) Profiling signaling polarity in chemotactic cells. Proc Natl Acad Sci U S A 104, 8328-33 17494752 Curated Info
174	Stokes M (2007) CST Curation Set: 2956; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
175	Gu T (2007) CST Curation Set: 2606; Year: 2007; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
176	Gu T (2007) CST Curation Set: 2582; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
177	Gu T (2007) CST Curation Set: 2583; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
178	Gu T (2007) CST Curation Set: 2592; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
179	Moritz A (2006) CST Curation Set: 1922; Year: 2006; Biosample/Treatment: cell line, Molm 14/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
180	Moritz A (2006) CST Curation Set: 1924; Year: 2006; Biosample/Treatment: cell line, Molm 14/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
181	Yu J (2006) CST Curation Set: 1914; Year: 2006; Biosample/Treatment: cell line, Kyse140/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
182	Yu J (2006) CST Curation Set: 1915; Year: 2006; Biosample/Treatment: cell line, Kyse140/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
183	Moritz A (2006) CST Curation Set: 1897; Year: 2006; Biosample/Treatment: cell line, MV4-11/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
184	Moritz A (2006) CST Curation Set: 1899; Year: 2006; Biosample/Treatment: cell line, MV4-11/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
185	Moritz A (2006) CST Curation Set: 1833; Year: 2006; Biosample/Treatment: cell line, SEM/Flt3 inhibitor; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
186	Moritz A (2006) CST Curation Set: 1835; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
187	Moritz A (2006) CST Curation Set: 1825; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
188	Moritz A (2006) CST Curation Set: 1823; Year: 2006; Biosample/Treatment: cell line, SEM/Flt3 inhibitor; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
189	Yu J (2006) CST Curation Set: 1802; Year: 2006; Biosample/Treatment: cell line, Kyse270/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
190	Moritz A (2006) CST Curation Set: 1784; Year: 2006; Biosample/Treatment: cell line, HEL/Flt3 inhibitor; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
191	Moritz A (2006) CST Curation Set: 1786; Year: 2006; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
192	Possemato A (2006) CST Curation Set: 1731; Year: 2006; Biosample/Treatment: cell line, NCI-H128/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
193	Possemato A (2006) CST Curation Set: 1732; Year: 2006; Biosample/Treatment: cell line, NCI-H128/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
194	Possemato A (2006) CST Curation Set: 1733; Year: 2006; Biosample/Treatment: cell line, NCI-H446/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
195	Possemato A (2006) CST Curation Set: 1734; Year: 2006; Biosample/Treatment: cell line, NCI-H446/0.5% serum; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
196	Farnsworth C (2005) CST Curation Set: 803; Year: 2005; Biosample/Treatment: tissue, lung/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
197	Farnsworth C (2005) CST Curation Set: 772; Year: 2005; Biosample/Treatment: tissue, /-; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
198	Farnsworth C (2005) CST Curation Set: 754; Year: 2005; Biosample/Treatment: cell line, DMS79/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
199	Farnsworth C (2005) CST Curation Set: 759; Year: 2005; Biosample/Treatment: cell line, DMS53/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
200	Moritz A (2005) CST Curation Set: 587; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
201	Moritz A (2005) CST Curation Set: 589; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
202	Moritz A (2005) CST Curation Set: 590; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
203	Farnsworth C (2004) CST Curation Set: 497; Year: 2004; Biosample/Treatment: cell line, DMS153/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
204	Rikova K (2004) CST Curation Set: 473; Year: 2004; Biosample1/Treatment/Isotope: cell line, NCI-H1703/untreated/L, Biosample2/Treatment/Isotope: cell line, NCI-H1703/untreated/Gleevec/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
205	Farnsworth C (2004) CST Curation Set: 464; Year: 2004; xenograft, Biosample/Treatment: cell line, NCI-H69/-; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
206	Goss V (2004) CST Curation Set: 442; Year: 2004; Biosample/Treatment: cell line, MEC1/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
207	Goss V (2004) CST Curation Set: 443; Year: 2004; Biosample/Treatment: cell line, MEC2/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
208	Farnsworth C (2004) CST Curation Set: 440; Year: 2004; Biosample/Treatment: cell line, NCI-H526/-; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
209	Guo A (2004) CST Curation Set: 624; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/calyculin/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/calyculin/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
210	Guo A (2004) CST Curation Set: 625; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/Iressa/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
211	Guo A (2004) CST Curation Set: 327; Year: 2004; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
212	Guo A (2004) CST Curation Set: 328; Year: 2004; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
213	Goss V (2004) CST Curation Set: 333; Year: 2004; Biosample/Treatment: blood, B lymphoid/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info